+

ZA200600733B - Treatment and prevention of cardiovascular events - Google Patents

Treatment and prevention of cardiovascular events

Info

Publication number
ZA200600733B
ZA200600733B ZA200600733A ZA200600733A ZA200600733B ZA 200600733 B ZA200600733 B ZA 200600733B ZA 200600733 A ZA200600733 A ZA 200600733A ZA 200600733 A ZA200600733 A ZA 200600733A ZA 200600733 B ZA200600733 B ZA 200600733B
Authority
ZA
South Africa
Prior art keywords
prevention
treatment
cardiovascular events
cardiovascular
events
Prior art date
Application number
ZA200600733A
Other languages
English (en)
Inventor
Sasmal Badal Kumar
Nasare Vijay Dinanathji
Reddy Billa Praveen
Mohan Mailutur Sivaraman
Original Assignee
Reddys Lab Inc Dr
Reddys Lab Ltd Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IN604CH2003 external-priority patent/IN206994B/en
Application filed by Reddys Lab Inc Dr, Reddys Lab Ltd Dr filed Critical Reddys Lab Inc Dr
Publication of ZA200600733B publication Critical patent/ZA200600733B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200600733A 2003-07-28 2006-01-25 Treatment and prevention of cardiovascular events ZA200600733B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN604CH2003 IN206994B (xx) 2000-10-25 2001-10-25

Publications (1)

Publication Number Publication Date
ZA200600733B true ZA200600733B (en) 2007-07-25

Family

ID=34090476

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200600733A ZA200600733B (en) 2003-07-28 2006-01-25 Treatment and prevention of cardiovascular events

Country Status (10)

Country Link
US (2) US20050026992A1 (xx)
EP (1) EP1648422A4 (xx)
CN (1) CN1822820A (xx)
AU (1) AU2004261212B2 (xx)
BR (1) BRPI0412557A (xx)
CA (1) CA2531279A1 (xx)
NZ (1) NZ544784A (xx)
RU (1) RU2380093C2 (xx)
WO (1) WO2005011586A2 (xx)
ZA (1) ZA200600733B (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011586A2 (en) * 2003-07-28 2005-02-10 Dr. Reddy's Laboratories, Inc. Treatment and preventi0n of cardiovascular events
US20090117197A1 (en) * 2005-03-21 2009-05-07 Vicus Therapeutics Llc Compositions and methods for ameliorating cachexia
JP5273721B2 (ja) * 2005-03-21 2013-08-28 ビカス セラピューティクス,エルエルシー 悪液質を緩和するための組成物および方法
US20070009591A1 (en) * 2005-07-07 2007-01-11 Trivedi Jay S ACE inhibitor formulation
WO2007020079A2 (en) * 2005-08-17 2007-02-22 Synthon B.V. Orally disintegratable simvastatin tablets
WO2007049291A1 (en) * 2005-10-27 2007-05-03 Lupin Limited Novel solid dosage forms of valsartan and rochlorothiazide
MX2008006453A (es) * 2005-11-18 2009-01-28 Accu Break Technologies Inc Formas segmentadas de dosis farmaceutica.
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
US20070185065A1 (en) * 2006-02-03 2007-08-09 Vikramjit Chhokar Combination therapy for coronary artery disease
ES2300188B1 (es) * 2006-05-24 2009-05-01 Ferrer Internacional, S.A. Comprimido bicapa para la prevencion de los accidentes cardiovasculares.
WO2008001184A2 (en) * 2006-06-26 2008-01-03 Emcure Pharmaceuticals Limited Solid composition
US20080107726A1 (en) * 2006-11-01 2008-05-08 Pramod Kharwade Compositions comprising beta-adrenergic receptor antagonists and diuretics
CN101980701A (zh) * 2008-03-28 2011-02-23 菲尔若国际公司 用于预防心血管疾病的胶囊
CN101590239B (zh) * 2008-05-30 2013-03-27 北京奥萨医药研究中心有限公司 含有利尿剂、他汀和叶酸的药物组合物及其用途
AU2010212580B2 (en) * 2009-02-11 2015-11-12 Cadila Pharmaceuticals Ltd. Stable pharmaceutical composition for atherosclerosis
MX357919B (es) * 2009-03-13 2018-07-25 Nucitec Sa De Cv Composición farmacéutica para el tratamiento de la hipercolesterolemia.
AU2010242938A1 (en) * 2009-04-30 2011-11-17 Dr. Reddy's Laboratories Ltd. Fixed dose drug combination formulations
CN101897710A (zh) * 2009-05-27 2010-12-01 北京奥萨医药研究中心有限公司 含有HMG-CoA还原酶抑制剂、阿司匹林、叶酸的药物组合物及其用途
US9056134B2 (en) * 2010-07-21 2015-06-16 Nucitec S.A. De C.V. Single daily dosage form for prevention and treatment of metabolic syndrome
GB201116993D0 (en) * 2011-10-03 2011-11-16 Ems Sa Pharmaceutical compositions of antihypertensives
RU2491070C2 (ru) * 2011-10-11 2013-08-27 Общество с ограниченной ответственностью "Фармамед" Фармацевтическая композиция для профилактики и лечения сердечно-сосудистых заболеваний
CN102357084B (zh) * 2011-10-11 2014-02-26 广东彼迪药业有限公司 一种马来酸依那普利的片剂组合物及其制备与应用
CN102671198A (zh) * 2011-12-17 2012-09-19 东莞达信生物技术有限公司 一种降压降脂复方药及其制备方法
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
PH12018502155B1 (en) * 2016-04-20 2024-03-27 Servier Lab Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid
CN107184952A (zh) * 2017-06-13 2017-09-22 江苏黄河药业股份有限公司 一种赖诺普利复方制剂及其制备方法
CN110237258A (zh) * 2018-03-09 2019-09-17 深圳奥萨制药有限公司 用于治疗高血压的药物组合物
WO2020214163A1 (en) * 2019-04-17 2020-10-22 CardioPharma, Inc. Anti-hypertensive and cholesterol-lowering fixed-dose combination and method of manufacture
WO2021202457A1 (en) * 2020-03-30 2021-10-07 Exagen Inc. Cardiovascular biomarkers for systemic lupus erythematosus

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622985A (en) 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US6251852B1 (en) * 1996-09-18 2001-06-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6235311B1 (en) 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6121249A (en) * 1998-07-01 2000-09-19 Donald L. Weissman Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins
US6323188B1 (en) * 1998-07-01 2001-11-27 Donald L. Weissman Treatment and prevention of cardiovascular diseases, heart attack, and stroke, primary and subsequent, with help of aspirin and certain vitamins
ES2246894T3 (es) * 1999-08-30 2006-03-01 Sanofi-Aventis Deutschland Gmbh Ramipril para la prevencion de sucesos cardiovasculares.
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
CA2406077C (en) 2000-04-10 2010-07-20 Nicholas J. Wald Formulation for the prevention of cardiovascular disease
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20040116510A1 (en) * 2002-03-05 2004-06-17 Nichtberger Steven A. Antihypertensive agent and cholesterol absorption inhibitor combination therapy
WO2003090723A1 (en) * 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
MXPA04011227A (es) * 2002-05-17 2005-01-25 Esperion Therapeutics Inc Metodos y composiciones para el tratamiento de la reperfusion isquemica.
NZ539013A (en) * 2002-10-03 2007-05-31 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
WO2004052373A1 (en) * 2002-12-06 2004-06-24 Warner-Lambert Company Llc Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
AU2003303231A1 (en) * 2002-12-20 2004-07-14 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
ES2331131T3 (es) * 2003-05-20 2009-12-22 Novartis Ag Heterociclos de nitrogeno n-acil como ligandos de los receptores activados por los proliferadores de las peroximas.
JP2009513523A (ja) * 2003-07-08 2009-04-02 ノバルティス アクチエンゲゼルシャフト ベンゼンスルホニルアミノ化合物およびそれらを含む医薬組成物
WO2005011586A2 (en) * 2003-07-28 2005-02-10 Dr. Reddy's Laboratories, Inc. Treatment and preventi0n of cardiovascular events
US20050053648A1 (en) * 2003-09-08 2005-03-10 Chalmers Anne Marie Medication delivery device
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions

Also Published As

Publication number Publication date
US20100068269A1 (en) 2010-03-18
NZ544784A (en) 2009-11-27
WO2005011586A3 (en) 2005-07-07
EP1648422A2 (en) 2006-04-26
EP1648422A4 (en) 2007-09-19
AU2004261212A1 (en) 2005-02-10
CA2531279A1 (en) 2005-02-10
AU2004261212B2 (en) 2011-01-27
WO2005011586A2 (en) 2005-02-10
US20050026992A1 (en) 2005-02-03
BRPI0412557A (pt) 2006-09-19
CN1822820A (zh) 2006-08-23
RU2006102356A (ru) 2007-09-10
RU2380093C2 (ru) 2010-01-27

Similar Documents

Publication Publication Date Title
ZA200600733B (en) Treatment and prevention of cardiovascular events
TWI347188B (en) Treatment and prevention of osteoporosis
AU2003290548A8 (en) Prevention and treatment of synucleinopathic disease
SI2075000T1 (sl) Kombinacija azelastina in ciklezonida
HK1152474A1 (en) Methods and compositions for the prevention and treatment of sepsis
IL178996A0 (en) Thienopyridinone compounds and methods of treatment
IL182436A0 (en) Thienopyridinone compounds and methods of treatment
AU2003291480A8 (en) Composition for the prevention and treatment of inflammation of the ear
IL149251A0 (en) Diagnosis and treatment of cardiovascular conditions
GB2407823B (en) Surface treatment of magnesium and its alloys
EP1786265A4 (en) NEW COMPOSITIONS AND PROCESSING METHODS
AU2002359747A8 (en) Prevention and treatment of atherosclerosis and restenosis
GB0324523D0 (en) Compositions and methods of treatment
AU2003301819A8 (en) Compositions and methods for prevention of photoaging
AU2003231279A8 (en) Prevention and treatment of type 2 diabetes
EP1560592A4 (en) TREATMENT OF ALLGIELES
EP1573063A4 (en) TREATMENT OF LIVER DISEASES
GB0221712D0 (en) Methods of treatment
IL166083A0 (en) Methods for treatment and prevention of gastrointestinal conditions
GB0419175D0 (en) Method of treatment and compositions
IL151658A0 (en) Methods and compositions for the treatment or prevention of cardiovascular diseases
AU2003251751A8 (en) Agents capable of inhibiting ras and uses thereof
AU2003276123A8 (en) Treatment of uveal melanoma
GB0305699D0 (en) Therapeutic compositions and methods
AU2003213256A8 (en) Treatment and prevention of aids progression and methods of using same
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载